- Home
- DUO vs BIVI Comparison
DUO vs BIVI Comparison
Compare DUO & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DUO | BIVI |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 8.7M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | DUO | BIVI |
|---|---|---|
| Price | $1.59 | $1.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 66.1K | ★ 132.7K |
| Earning Date | 03-13-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $56,189,313.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 48.30 | N/A |
| 52 Week Low | $1.24 | $1.10 |
| 52 Week High | $11.46 | $22.90 |
Technical Indicators
Market Signals| Indicator | DUO | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 44.25 | 37.42 |
| Support Level | $1.54 | $1.14 |
| Resistance Level | $1.68 | $1.34 |
| Average True Range (ATR) | 0.09 | 0.09 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 40.00 | 26.15 |
Price Performance
Historical ComparisonAbout DUO Fangdd Network Group Ltd.
Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.